Participated in Solve Therapeutics' $120M financing to advance its antibody-drug conjugate pipeline for solid tumors.
Solve Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of next-generation antibody-drug conjugates (ADCs) and a novel diagnostic platform for solid tumors
Solve Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of next-generation antibody-drug conjugates (ADCs) and a novel diagnostic platform for solid tumors. With its proprietary CloakLink™ hydrophilic linker system and a focus on selectively expressed tumor antigens, Solve is engineering therapeutics designed to safely and effectively offer benefit to patients with life-threatening cancers.